To look forward we need to first look back. From 2008-2012 we saw big pharma collide creating larger companies. Genentech-Roche, Novartis-Alcon, Pfizer-Wyeth and GlaxoSmithKline-Human Genome Sciences just to name a few. During this same time frame the economies of the world have seen crashes and upheavals causing some of these same companies to “trim” their workforces. What does all this mean for 2013?
Economic worries will hold Operation Excellence in ch...
